Nurix Therapeutics is trading 5.1% down today at $21.89 as investors digest its recent Q2 2026 loss and revenue miss. This pullback also reflects profit-taking following a prior Roche deal-driven run-up.
- The company's quarterly results for Q2 2026 fell short of analyst expectations for both EPS and revenue.
- Investors are also locking in gains following a significant stock run-up driven by a global collaboration deal with Roche announced in June 2026.